azomycin has been researched along with Kahler Disease in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, L; Guo, J; Jiang, H; Li, X; Liu, B; Liu, J; Liu, Z; Peng, Z; Wan, C; Wang, J; Wang, S; Xie, Y; Xu, Y; Zhong, Y | 1 |
| De Bruyne, E; De Bryune, E; De Raeve, H; Handisides, D; Hart, CP; Hu, J; Menu, E; Van Camp, B; Van Valckenborgh, E; Vanderkerken, K; Xu, D; Xu, S | 1 |
| de Waal, EG; Kluin, PM; Leene, MJ; Slart, RH; Vellenga, E | 1 |
| De Raeve, H; Handisides, DR; Hart, CP; Hu, J; Liu, Q; Menu, E; Sun, JD; Van Camp, B; Van Valckenborgh, E; Vande Broek, I; Vanderkerken, K | 1 |
| Asosingh, K; De Raeve, H; de Ridder, M; Storme, GA; Van Camp, B; Van Riet, I; Vanderkerken, K; Willems, A | 1 |
| Boechat, N; Bozza, M; Carvalho, AS; Fernandez-Ferreira, E; Gibaldi, D; Pinto, AC; Soares, RO; Souza, AS | 1 |
6 other study(ies) available for azomycin and Kahler Disease
| Article | Year |
|---|---|
Hypoxia-induced CREB cooperates MMSET to modify chromatin and promote DKK1 expression in multiple myeloma.
Topics: Chromatin; Cyclic AMP Response Element-Binding Protein; Gene Expression Regulation, Neoplastic; Histone-Lysine N-Methyltransferase; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Intercellular Signaling Peptides and Proteins; Multiple Myeloma; Nitroimidazoles; Osteoblasts; Osteolysis; Phosphoramide Mustards; Repressor Proteins; Tumor Hypoxia; Wnt Signaling Pathway | 2021 |
Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Screening Assays, Antitumor; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred C57BL; Multiple Myeloma; Nitroimidazoles; Phosphoramide Mustards; Pyrazines; Signal Transduction | 2013 |
18F-FDG PET increases visibility of bone lesions in relapsed multiple myeloma: is this hypoxia-driven?
Topics: Basic Helix-Loop-Helix Transcription Factors; Bone Marrow; Bone Neoplasms; Cell Hypoxia; Female; Fluorodeoxyglucose F18; Glucose Transporter Type 1; Glucose Transporter Type 3; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Middle Aged; Multiple Myeloma; Nitroimidazoles; Positron-Emission Tomography; Radiopharmaceuticals; Vascular Endothelial Growth Factor A | 2015 |
Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug.
Topics: Animals; Apoptosis; Blotting, Western; Bone Marrow; Caspases; Cell Cycle; Cell Cycle Proteins; Cell Proliferation; Humans; Hypoxia; Male; Mice; Mice, Inbred C57BL; Multiple Myeloma; Neovascularization, Pathologic; Nitroimidazoles; Oxygen; Phosphoramide Mustards; Prodrugs; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2010 |
Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression.
Topics: Animals; Apoptosis; Bone Marrow Cells; Caspase 3; Caspases; Cell Hypoxia; Disease Progression; Flow Cytometry; Hematopoiesis; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Leukocyte Common Antigens; Mice; Multiple Myeloma; Neovascularization, Pathologic; Nitroimidazoles | 2005 |
Novel nitroimidazoles with trypanocidal and cell growth inhibition activities.
Topics: Animals; Chagas Disease; Dose-Response Relationship, Drug; Erythrocytes; Mice; Monocytes; Multiple Myeloma; Nitroimidazoles; Sheep; Trypanocidal Agents; Trypanosoma cruzi; Tumor Cells, Cultured | 2001 |